Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab

37Citations
Citations of this article
70Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpopulation of CD4-positive (CD4+) T lymphocytes from blood, with high levels of cell activation and heterogeneous memory phenotypes. In lymph node samples from infected patients, CD20 is present in productively HIV-infected cells, and ex vivo viral infection selectively upregulates the expression of CD20 during early infection. In samples from patients on antiretroviral therapy (ART) this subpopulation is significantly enriched in HIV transcripts, and the anti-CD20 monoclonal antibody Rituximab induces cell killing, which reduces the pool of HIV-expressing cells when combined with latency reversal agents. We provide a tool for targeting this active HIV-reservoir after viral reactivation in patients while on ART.

Cite

CITATION STYLE

APA

Serra-Peinado, C., Grau-Expósito, J., Luque-Ballesteros, L., Astorga-Gamaza, A., Navarro, J., Gallego-Rodriguez, J., … Buzon, M. J. (2019). Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-11556-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free